| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment.
|
Proc Natl Acad Sci U S A
|
2009
|
4.19
|
|
2
|
Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab.
|
Clin Cancer Res
|
2009
|
2.14
|
|
3
|
Che-1 phosphorylation by ATM/ATR and Chk2 kinases activates p53 transcription and the G2/M checkpoint.
|
Cancer Cell
|
2006
|
1.38
|
|
4
|
Cornelia de Lange syndrome mutations in SMC1A or SMC3 affect binding to DNA.
|
Hum Mol Genet
|
2008
|
1.37
|
|
5
|
Mild hypoxia enhances proliferation and multipotency of human neural stem cells.
|
PLoS One
|
2010
|
1.35
|
|
6
|
DBC1 phosphorylation by ATM/ATR inhibits SIRT1 deacetylase in response to DNA damage.
|
J Mol Cell Biol
|
2012
|
1.20
|
|
7
|
Bcl-2 phosphorylation and apoptosis activated by damaged microtubules require mTOR and are regulated by Akt.
|
Oncogene
|
2004
|
1.17
|
|
8
|
Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2.
|
Oncogene
|
2004
|
1.16
|
|
9
|
Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2.
|
Mol Cancer Ther
|
2007
|
1.13
|
|
10
|
Activation of ATM and Chk2 kinases in relation to the amount of DNA strand breaks.
|
Oncogene
|
2004
|
1.12
|
|
11
|
Impaired elimination of DNA double-strand break-containing lymphocytes in ataxia telangiectasia and Nijmegen breakage syndrome.
|
DNA Repair (Amst)
|
2006
|
1.08
|
|
12
|
DNA damage-induced cell cycle regulation and function of novel Chk2 phosphoresidues.
|
Mol Cell Biol
|
2006
|
1.07
|
|
13
|
Karyopherin-alpha2 protein interacts with Chk2 and contributes to its nuclear import.
|
J Biol Chem
|
2003
|
1.06
|
|
14
|
A CDKN2A mutation in familial melanoma that abrogates binding of p16INK4a to CDK4 but not CDK6.
|
Cancer Res
|
2007
|
1.05
|
|
15
|
Long-term survival of human neural stem cells in the ischemic rat brain upon transient immunosuppression.
|
PLoS One
|
2010
|
1.05
|
|
16
|
Hypoxia in the regulation of neural stem cells.
|
Cell Mol Life Sci
|
2011
|
1.04
|
|
17
|
Ataxia-telangiectasia-mutated dependent phosphorylation of Artemis in response to DNA damage.
|
Cancer Sci
|
2005
|
1.01
|
|
18
|
Damaging-agent sensitivity of Artemis-deficient cell lines.
|
Eur J Immunol
|
2005
|
1.00
|
|
19
|
TLR9 agonists oppositely modulate DNA repair genes in tumor versus immune cells and enhance chemotherapy effects.
|
Cancer Res
|
2011
|
1.00
|
|
20
|
TRAP1 regulates proliferation, mitochondrial function, and has prognostic significance in NSCLC.
|
Mol Cancer Res
|
2014
|
0.99
|
|
21
|
Phenotypic variations between affected siblings with ataxia-telangiectasia: ataxia-telangiectasia in Japan.
|
Int J Hematol
|
2009
|
0.99
|
|
22
|
The shelterin protein TRF2 inhibits Chk2 activity at telomeres in the absence of DNA damage.
|
Curr Biol
|
2009
|
0.97
|
|
23
|
Designing Smac-mimetics as antagonists of XIAP, cIAP1, and cIAP2.
|
Biochem Biophys Res Commun
|
2008
|
0.96
|
|
24
|
Brap2 functions as a cytoplasmic retention protein for p21 during monocyte differentiation.
|
Mol Cell Biol
|
2004
|
0.95
|
|
25
|
SEL1L affects human pancreatic cancer cell cycle and invasiveness through modulation of PTEN and genes related to cell-matrix interactions.
|
Neoplasia
|
2005
|
0.93
|
|
26
|
A protein phosphatase feedback mechanism regulates the basal phosphorylation of Chk2 kinase in the absence of DNA damage.
|
Biochim Biophys Acta
|
2010
|
0.92
|
|
27
|
NFBD1/MDC1 associates with p53 and regulates its function at the crossroad between cell survival and death in response to DNA damage.
|
J Biol Chem
|
2007
|
0.92
|
|
28
|
ATM and the DNA damage response. Workshop on ataxia-telangiectasia and related syndromes.
|
EMBO Rep
|
2006
|
0.92
|
|
29
|
Detection of ATM gene mutation in human glioma cell line M059J by a rapid frameshift/stop codon assay in yeast.
|
Radiat Res
|
2002
|
0.91
|
|
30
|
Dimeric Smac mimetics/IAP inhibitors as in vivo-active pro-apoptotic agents. Part II: Structural and biological characterization.
|
Bioorg Med Chem
|
2012
|
0.90
|
|
31
|
Rational design, synthesis and characterization of potent, non-peptidic Smac mimics/XIAP inhibitors as proapoptotic agents for cancer therapy.
|
Bioorg Med Chem
|
2009
|
0.89
|
|
32
|
Comparative neuronal differentiation of self-renewing neural progenitor cell lines obtained from human induced pluripotent stem cells.
|
Front Cell Neurosci
|
2013
|
0.88
|
|
33
|
REGgamma proteasome activator is involved in the maintenance of chromosomal stability.
|
Cell Cycle
|
2007
|
0.88
|
|
34
|
Role of senataxin in DNA damage and telomeric stability.
|
DNA Repair (Amst)
|
2010
|
0.87
|
|
35
|
Novel second mitochondria-derived activator of caspases (Smac) mimetic compounds sensitize human leukemic cell lines to conventional chemotherapeutic drug-induced and death receptor-mediated apoptosis.
|
Invest New Drugs
|
2010
|
0.87
|
|
36
|
REGgamma/PA28gamma proteasome activator interacts with PML and Chk2 and affects PML nuclear bodies number.
|
Cell Cycle
|
2009
|
0.87
|
|
37
|
Regulation of lipocalin-2 gene by the cancer chemopreventive retinoid 4-HPR.
|
Int J Cancer
|
2006
|
0.85
|
|
38
|
Recognition of Smac-mimetic compounds by the BIR domain of cIAP1.
|
Protein Sci
|
2010
|
0.85
|
|
39
|
Missense mutation and defective function of ATM in a childhood acute leukemia patient with MLL gene rearrangement.
|
Blood
|
2003
|
0.85
|
|
40
|
Structural basis for bivalent Smac-mimetics recognition in the IAP protein family.
|
J Mol Biol
|
2009
|
0.84
|
|
41
|
Targeting the X-linked inhibitor of apoptosis protein through 4-substituted azabicyclo[5.3.0]alkane smac mimetics. Structure, activity, and recognition principles.
|
J Mol Biol
|
2008
|
0.84
|
|
42
|
Single-agent Smac-mimetic compounds induce apoptosis in B chronic lymphocytic leukaemia (B-CLL).
|
Leuk Res
|
2013
|
0.84
|
|
43
|
Chk2 phosphorylation of survivin-DeltaEx3 contributes to a DNA damage-sensing checkpoint in cancer.
|
Cancer Res
|
2012
|
0.82
|
|
44
|
ATM-deficient human neural stem cells as an in vitro model system to study neurodegeneration.
|
DNA Repair (Amst)
|
2013
|
0.81
|
|
45
|
Differential pathotropism of non-immortalized and immortalized human neural stem cell lines in a focal demyelination model.
|
Cell Mol Life Sci
|
2011
|
0.81
|
|
46
|
Functional analysis and molecular modeling show a preserved wild-type activity of p53(C238Y).
|
Mol Cancer Ther
|
2006
|
0.79
|
|
47
|
Identification and characterization of polymorphic variations of the ataxia telangiectasia mutated (ATM) gene in childhood Hodgkin disease.
|
Blood
|
2003
|
0.79
|
|
48
|
Structural insight into inhibitor of apoptosis proteins recognition by a potent divalent smac-mimetic.
|
PLoS One
|
2012
|
0.79
|
|
49
|
Two new CHEK2 germ-line variants detected in breast cancer/sarcoma families negative for BRCA1, BRCA2, and TP53 gene mutations.
|
Breast Cancer Res Treat
|
2011
|
0.78
|
|
50
|
A novel defect in mitochondrial p53 accumulation following DNA damage confers apoptosis resistance in Ataxia Telangiectasia and Nijmegen Breakage Syndrome T-cells.
|
DNA Repair (Amst)
|
2010
|
0.77
|
|
51
|
Antitumor activity of a novel homodimeric SMAC mimetic in ovarian carcinoma.
|
Mol Pharm
|
2013
|
0.77
|
|
52
|
Brain and induced pluripotent stem cell-derived neural stem cells as an in vitro model of neurodegeneration in ataxia-telangiectasia.
|
Exp Biol Med (Maywood)
|
2013
|
0.77
|